| Ytd | -70.58% | |
| 1y | -94.40% |
| Open | 1.65 | Prev Close | 1.57 | Low | 1.65 | High | 1.89 | Mkt Cap | 7.81M |
| Vol | 100.28K | Avg Vol | 80.36K | EPS | -10.24 | P/E | N/A | Forward P/E | -2.27 |
| Beta | 1.75 | Short Ratio | 10.06 | Inst. Own | 86.03% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-09 | 50-d Avg | 3.47 | 200-d Avg | 5.83 | 1yr Est | 18.00 |
Skye Bioscience, Inc. (NASDAQ: SKYE - Get Free Report) major shareholder 5Am Partners Vii, Llc sold
Skye Bioscience, Inc. (NASDAQ: SKYE - Get Free Report) Director Andrew Schwab sold 33,892 shares of
Gainers Opus Genetics (NASDAQ:IRD) shares increased by 31.7% to $5.71 during Wednesday's regula
Gainers Redhill Biopharma (NASDAQ:RDHL) shares increased by 96.7% to $1.3 during Monday's pre-m
Skye Bioscience shares rise 6% after hours on a $22M equity purchase agreement and warrant issuance.
Entry into a Material Definitive Agreement. As previously disclosed on the Current Report on Form 8-